When to Start DAA Therapy for Chronic HCV
All patients with chronic HCV infection should be treated with DAA therapy as soon as the diagnosis is confirmed, with treatment initiation prioritized based on disease severity and risk of transmission. 1, 2
General Principle: Treat All, Prioritize Urgently
The modern approach is straightforward: every HCV infection represents an indication for antiviral treatment 3. The question is not "if" but "when," with urgency determined by specific clinical factors.
Immediate Treatment Priority (Treat First)
Start DAA therapy immediately in these populations:
- Decompensated cirrhosis (Child-Pugh B or C) - these patients have the highest mortality risk 1, 4
- Compensated cirrhosis (Child-Pugh A) - annual HCC risk of 1-7% 1
- Significant fibrosis (≥F3) - progressive liver disease 3
- HCC candidates awaiting liver transplantation in centers with long waiting times - reduces waitlist dropout from tumor progression 1
- HBV coinfection with detectable HBs antigen - requires concurrent nucleoside/nucleotide analogue prophylaxis 1
- Recently acquired HCV infection (duration <12 months) - prevents transmission and achieves micro-elimination 1
- Patients at high risk of transmission (active injection drug users, HIV-positive individuals, healthcare workers)
Timing Considerations for Specific Populations
HCC Without Cirrhosis or With Compensated Cirrhosis
Defer DAA therapy until after curative HCC treatment (resection or ablation) is completed 1. The rationale: lower SVR rates occur when treating active HCC (88% vs 92% without HCC), and treatment should not interfere with oncologic management.
Exception: For HCC patients awaiting transplantation, timing must be individualized through multidisciplinary discussion, particularly in centers with long waiting times where pre-transplant treatment facilitates locoregional therapies 1.
Recently Acquired (Acute) HCV Infection
Start treatment at 8 weeks for recently acquired de novo hepatitis C 1. Do not wait for chronicity criteria. Use sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for 8 weeks 1.
Critical point: There is no indication for post-exposure prophylaxis in the absence of documented HCV transmission 1. Wait for confirmed infection.
Chronic HCV Without Advanced Fibrosis
Start as early as possible once diagnosis is confirmed 2, 5. While these patients have lower immediate mortality risk, delaying treatment:
- Increases transmission risk
- Allows disease progression
- Delays the benefits of viral clearance
The only acceptable reason to delay in this population is if DAAs are not yet accessible and the patient's condition is stable 5.
Pre-Treatment Requirements
Before initiating DAA therapy, confirm:
- Chronic HCV infection (HCV RNA or core antigen positive)
- Exclude decompensated cirrhosis - calculate Child-Pugh score; score ≥7 requires specialized regimens 2
- Screen for HBV coinfection - test HBs antigen, anti-HBc, anti-HBs 1
- Rule out pregnancy 2
- Assess renal function - eGFR affects regimen selection 1
- For cirrhosis patients: liver ultrasound within 6 months to exclude HCC 2
Common Pitfalls to Avoid
- Don't wait for "chronic" criteria in recently acquired infection - this increases transmission risk and is cost-ineffective 1
- Don't treat HCC patients before curative therapy unless they're transplant candidates with long wait times 1
- Don't forget HBV screening - reactivation can occur during/after DAA therapy, requiring prophylaxis 1
- Don't delay treatment in substance users - they should be treated immediately to prevent transmission, though real-world data shows they're paradoxically less likely to receive treatment 6
Post-SVR Monitoring
- Cirrhosis patients: Lifelong HCC surveillance required even after SVR - risk is reduced but not eliminated 1, 3
- High-risk behaviors: Annual HCV RNA testing for reinfection 2
- No cirrhosis with SVR: No liver-specific follow-up needed 2
The paradigm has shifted from "watch and wait" to "treat all now," with the only variable being the urgency based on disease severity and transmission risk.